| Program | tRNA Synthetase | Target/MOA | Indication | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|---|---|
| Efzofitimod | HARS | NRP2 modulator | Pulmonary Sarcoidosis(1) |
|
|||
| SSc-ILD |
|
||||||
| Other ILD (CTD-ILD; CHP) |
|
||||||
| ATYR0101 | DARS | LTBP1 modulator | Fibrosis |
|
|||
| ATYR0750 | AARS | FGFR4 modulator | Liver Disorders |
|
|||
| tRNA Synthetase Candidates(2) |
|
||||||
| Program/ Target |
Indication | Phase |
|---|---|---|
| Efzofitimod NRP2 modulator |
Pulmonary Sarcoidosis(1) | Phase 3 |
| SSc-ILD | Phase 2 | |
| Other ILD (CTD-ILD; CHP) | Phase 1 | |
| ATYR0101 LTBP1 modulator |
Fibrosis | Preclinical |
| ATYR0750 FGFR4 modulator |
Liver Disorders | Preclinical |
| tRNA Synthetase Candidates(2) | Preclinical |
(1) In partnership with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILD in Japan
(2) Pipeline candidates in development based on additional tRNA synthetases from IP portfolio
ODD = orphan drug designation; SSc-ILD = Scleroderma-related ILD; CTD-ILD = Connective Tissue Disease-ILD; CHP = Chronic Hypersensitivity Pneumonitis